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Abstract
Background: Mast cells play a critical role in allergic and inflammatory diseases, including exercise-induced
bronchoconstriction (EIB) in asthma. The mechanism underlying EIB is probably related to increased airway fluid osmolarity
that activates mast cells to the release inflammatory mediators. These mediators then act on bronchial smooth muscle to
cause bronchoconstriction. In parallel, protective substances such as prostaglandin E2 (PGE2) are probably also released and
could explain the refractory period observed in patients with EIB.
Objective: This study aimed to evaluate the protective effect of PGE2 on osmotically activated mast cells, as a model of
exercise-induced bronchoconstriction.
Methods:We used LAD2, HMC-1, CD34-positive, and human lung mast cell lines. Cells underwent a mannitol challenge, and
the effects of PGE2 and prostanoid receptor (EP) antagonists for EP1–4 were assayed on the activated mast cells. Beta-
hexosaminidase release, protein phosphorylation, and calcium mobilization were assessed.
Results: Mannitol both induced mast cell degranulation and activated phosphatidyl inositide 3-kinase and mitogen-
activated protein kinase (MAPK) pathways, thereby causing de novo eicosanoid and cytokine synthesis. The addition of
PGE2 significantly reduced mannitol-induced degranulation through EP2 and EP4 receptors, as measured by beta-
hexosaminidase release, and consequently calcium influx. Extracellular-signal-regulated kinase 1/2, c-Jun N-terminal kinase,
and p38 phosphorylation were diminished when compared with mannitol activation alone.
Conclusions: Our data show a protective role for the PGE2 receptors EP2 and EP4 following osmotic changes, through the
reduction of human mast cell activity caused by calcium influx impairment and MAP kinase inhibition.
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Introduction
Asthma is a complex chronic inflammatory disease of the
airways that involves the activation of many inflammatory and
structural cells. Each component releases inflammatory mediators
that result in the pathophysiological changes of typical of the
condition [1]. Human mast cells (HuMC) are recognized as the
key effector cells of allergic and non-allergic inflammation in
asthma [2]. In addition to allergens, many non-immunological
stimuli activate complex signaling cascades in mast cells that lead
to the secretion of a plethora of autacoid mediators, cytokines, and
proteases [3].
Exercise-induced bronchoconstriction (EIB) is a condition in
which vigorous physical activity triggers acute airway narrowing.
EIB occurs in response to a loss of water from the airways caused
by hyperventilation associated with exercise. The osmotic theory
proposes that the primary effect of airway water loss is the
induction of an increased osmolality in the airway surface liquid
[4] that stimulates the release of various mediators via mast cell
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mechanisms. Both the epithelium and eosinophils may be involved
in the generation of EIB-related mediators [5,6].
Experimental surrogates for exercise include the inhalation of
hyperosmolar agents and mannitol drug powder [7]. The mannitol
challenge is an indirect bronchial challenge [8], which exerts an
osmotic effect on the airways and consequently has the potential to
lead to mast cell activation [7], [9,10], [11]. Thus, it can mimic the
effects of exercise on airway fluid osmolarity.
Prostaglandin E2 (PGE2) is a product of the cyclooxygenase
pathway of arachidonic acid metabolism that is produced in mast
cells, dendritic cells, epithelial cells, fibroblasts, and macrophages.
Clinical studies have shown that experimental treatment with
PGE2 prevents allergen-, exercise-, and aspirin-induced airway
obstruction [12], [13]. Furthermore, several studies have shown a
link between asthmatic patients and low levels of PGE2 in isolated
airway cells [14], [15], [16], suggesting a homeostatic role for
PGE2 in the control of airway reactivity and/or inflammation.
PGE2 is a highly pluripotent prostanoid displaying a wide range
of pro-inflammatory and anti-inflammatory effects in several
tissues. Although PGE2 is a potent pro-inflammatory mediator
[17], its role as an anti-inflammatory mediator is now being
studied [18,19]. In this context, it opposes the host inflammatory
response, which potentially limits collateral damage to neighboring
cells and tissues, thereby aiding the resolution of inflammation
[20]. This dual effect appears to be dependent on the cell type, the
tissue compartment, the state of cellular activation, and the
expression pattern of four prostanoid (EP) receptor subtypes [21].
The EP receptors are members of the G protein-coupled
receptor (GPCR) family. EP1 signals through Gaq, which
increases Ca2+ levels. EP2 and EP4 signal through Gas to increase
cyclic-AMP (cAMP) levels, while EP3 primarily signals through
Gai to decrease cAMP levels. Further diversity among EP
receptors is generated in both the EP1 and EP3 receptors by
alternatively spliced C-terminal variants, as discussed elsewhere
[22]. The EP2 receptor can downregulate antigen-mediated mast
cell responses through Gas-dependent production of cAMP,
whereas the EP3 receptor can up-regulate antigen-mediated mast
cell responses through enhanced calcium-dependent signaling
[23,24]. It has been suggested that differences in EP2 and EP3
receptor expression in mast cells could dictate the upregulation or
downregulation of antigen-mediated responses by PGE2. Thus,
the distribution and relative expression of these four receptor
subtypes provide a flexible system describing the ability of PGE2 to
evoke pleiotropic, sometimes opposing, tissue and cell actions [25].
Notably, the beneficial in vivo effects of PGE2 in murine models of
allergic asthma might be mediated through EP2 receptors in
airway mast cells [26,27].
This study aimed to evaluate how PGE2 modulates the response
to mannitol through prostanoid receptors as a model of exercise-
induced asthma in human mast cells, and to clarify the related
signaling events.
Materials and Methods
Cells, Antibodies, and Reagents
The LAD2 HuMC line, provided by Drs A Kirshenbaum and
DD Metcalfe (National Institutes of Health, Bethesda, MD), was
grown in StemPro-34 serum-free medium (Invitrogen Life
Technologies, Carlsbad, California), supplemented with Stem-
Pro-34 nutrient, L-glutamine (2 mM), penicillin (100 U/ml),
streptomycin (100 mg/ml), and 100 ng/ml recombinant stem cell
factor (SCF) (Amgen, Thousand Oaks, California) as described
elsewhere [28]. The human mast cell line 1 (HMC-1) was obtained
from JH Butterfield (Mayo Clinic, Rochester, Minnesota), and was
cultured in RPMI 1640 medium containing 10% (v/v) fetal bovine
serum and 1% (v/v) penicillin/streptomycin at 37uC in 5% CO2
as decribed elsewhere [29].
Primary HuMCs derived from CD34-positive peripheral blood
cells were obtained from National Institutes of Health by a
Material Transfer Agreement #2009-0776. Healthy donors gave
written informed consent. The National Institute of Allergy and
Infectious Diseases Institutional Review Board and Ethics
Committee approved the protocol (98-I-0027; principal investiga-
tor: Dr A Kirshenbaum). Primary HuMCs were differentiated
in vitro for 8 weeks in the presence of 100 ng/ml interleukin (IL)-6
and 100 ng/ml SCF, as described previously [30]. We used the
following antibodies: monoclonal anti-b-actin-peroxidase (Sigma-
Aldrich, St. Louis, MO); anti-p38 Thr180/Tyr182, anti–p-ERK
(i.e., extracellular-signal-regulated kinase 1/2) Thr202/Tyr204,
and anti–p-JNK (i.e., c-Jun N-terminal kinase) Thr183/Tyr185
(Cell Signaling Technology, Danvers, MAs); pAKT antibody was
from Santa Cruz Biotechnology, Santa Cruz, CA); PGE2 and
antibodies against the EP (Prostaglandin E2) receptors were from
Cayman Chemical (Ann Arbor, MI), except for EP-4 (Abcam,
Cambridge, UK); EP1/EP2 antagonist receptor AH6809 and EP4
antagonist receptor AH23848 (Sigma); and EP3 antagonist
receptor L-826266 (Merck, Darmstadt, Germany).
Human Lung Mast Cells Purification and Culture
Mast cells were isolated from lung tissue obtained from patients
undergoing lung resection for lung cancer. The study was
approved by the Hospital Clinic Committee on Human Clinical
Research, and by the Ethics Committee, (expedient number:
2012/7613, Hospital Clinic, Barcelona) and written informed
consent was obtained from all patients. Using immunoaffinity
magnetic selection, human lung mast cells (HLMCs) were
dispersed from macroscopically normal lung obtained within 1
hour of resection from lung cancer patients, as described
previously [31]. Final mast cell purity and viability were each
99%. HLMCs were cultured in Dulbecco’s modified Eagles
medium, 10% FCS, antibiotic/antimycotic solution, SCF
(100 ng/ml), IL-6 (50 ng/ml), and IL-10 (10 ng/ml) [31].
Beta-hexosaminidase release assay
HuMCs were stimulated with 10% mannitol in Tyrode’s buffer
(10 mM HEPES, 137 mM NaCl, 2.7 mM KCl, 0.4 mM NaH2
PO4, 1.8 mM CaCl2, 1.3 mM MgSO4, 5.6 mM glucose, and
0.025% BSA) for 30 minutes at 37uC. For PGE2 stimulation and
EP receptor antagonist assays we pre-incubated cells with a high
dose of the antagonists for 10 minutes, before incubating with
increasing PGE2 doses for 10 minutes each. Afterwards, cells were
activated with mannitol 10% for 30 minutes. We used the
following EP receptor antagonists: AH6809 (10 mM) blocking
receptors EP1 and EP2 [32], L826266 (30 mM) blocking receptor
EP3 [33], and AH23848 (10 mM) blocking receptor EP4 [34]. Mast
cell degranulation was monitored by b-hexosaminidase release, as
described previously [35]. The resulting b-hexosaminidase activity
was expressed as the percentage of maximum response (samples
treated with triton X-100), that is b-hexosaminidase release (%) =
[(sample release 2 spontaneous release)/(maximum release 2
spontaneous release)]6100.
Calcium mobilization
Calcium mobilization in LAD2 cells was followed by fluorimet-
ric analysis of cytoplasmic-free calcium with Fluo-4 AM fluores-
cent dye (Molecular Probes, Invitrogen) as described elsewhere
[36]. Briefly, 0.26106 cells/point were loaded with 5 mM Fluo-4-
AM for 30 minutes at 37uC in the dark, washed twice with
Prostaglandin E2 in Mast Cell Osmotic Activation
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Tyrode’s buffer, and resuspended. To measure calcium influx in
the absence of extracellular calcium, cells were washed and
resuspended with Tyrode’s buffer without calcium. Fluorimetric
measurements were by a Modulus II Microplate Multimode
Reader (Turner Biosystems, Promega, CA), according to the
manufacturer’s instructions. After defining basal conditions the
stimuli was added (time 0) and fluorimetric measures were done 10
more minutes. Each point was done by triplicate.
ELISA for PGE2
26106 cells were activated with 10% mannitol for 30 minutes
and 4 hours. Supernatants were collected and concentrations of
PGE2 were measured with enzyme immunoassay kits (Cayman
Chemical, Ann Arbor, Mich) according to the manufacturer’s
instructions.
Cell activation and immunoblotting
Cells were treated in Tyrode’s buffer for 15 minutes with either
10% mannitol stimulation and/or PGE2 at 10 mM. EP receptor
antagonist pretreatment was done 10 minutes before any cell
stimulation as follows: AH6809 (10 mM) blocking receptors EP1
and EP2 [32], L826266 (30 mM) blocking receptor EP3 [33], and
AH23848 (10 mM) blocking receptor EP4 [34]. For immunoblot-
ting experiments, cells were washed twice with ice-cold PBS and
dissolved in a lysis buffer (1% Triton X-100, 50 mM Tris
[pH 7.4], 150 mM NaCl, 20 mM octyl-b-glucoside, 100 mM
NaF, 1 mM Na3VO4, 1 mM PMSF 1 mM sodium pyrophos-
phate, and protease inhibitor mixture; Roche Molecular Bio-
chemical, Indianapolis, Indiana). Cell lysates were clarified by
centrifugation. The total cell lysates were separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and electrotransferred to polyvinylidene difluoride membranes
Table 1. Primers used to determine prostaglandin E2 receptor expression on LAD2 cells by quantitative PCR.
Gene Name 59-39 primer sequence Accession Number
bactin FW 59GAAACTACCTTCAACTCCATC-39 RW 59-CTAGAAGCATTTGCGGTGGAC-39 NM_001101
EP1 receptor FW 59-TGTCGGTATCATGGTGGTG-39 RW 59GGCCTCTGGTTGTGCTTAGA-39 NM_000955
EP2 receptor FW 59-GTCTGCTCCTTGCCTTTCAC-39
RW 59-CCTCAAAGGTCAGCCTGTTT-3
NM_000956
EP3 receptor FW 59-CCACCTTTTCTTCGCCTCTG-39 RW 59-TTTCTGCTTCTCCGTGTGTG-39 NM_198715*
EP4 receptor FW 59-TCCAGCACCATTCTTCACTG-39 RW 59-AACAAAGTGCCCAACAGGTC-39 NM_000958
*variant number 5 of the ten existing variants of the receptor.
doi:10.1371/journal.pone.0110870.t001
Figure 1. Mast cell degranulation is induced by mannitol in human mast cells. LAD2 mast cells were stimulated with mannitol (5%, 10%,
and 17%) for 30 minutes, and b-hexosaminidase release was measured (A). CD63 staining was performed in LAD2 cells after mannitol stimulation
(10%) for 30 minutes. Positive control was conducted with PMA plus ionomycin. Negative control (NC) means isotype staining (B). b-hexosaminidase
content was measured in the supernatants from activated LAD2 cells, CD34+ derived human mast cells, and human lung mast cells induced by
mannitol (10%) at 37uC for 30 minutes (C). Results are in triplicate and are the mean of three independent experiments expressed as mean 6
standard deviation. Statistical significance *p#0.05, **p#0.01, ***p#0.001) is relative to the unstimulated control cells.
doi:10.1371/journal.pone.0110870.g001
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(Millipore, Bedford, Massachusetts). Blots were probed with the
indicated antibodies, and proteins were visualized by enhanced
chemiluminescence (Santa Cruz Biotechnology).
RNA extraction and Real-time polymerase chain reaction
Total RNA was extracted with an RNAeasy Mini Kit (Qiagen,
Hilden, Germany) from 26106 LAD2 cells. We generated
complementary DNA from an mRNA High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems) according to the
manufacturer’s instructions. To amplify EP receptors from LAD2,
the primer pairs detailed in Table 1 were used.
Real-time polymerase chain reaction
Real-time polymerase chain reaction (RT-PCR) for EP1, EP2,
EP3, EP4, IL-8, and tumor necrosis factor (TNF) was performed
using the TaqMan Gene Expression Assay (Applied Biosystems)
on an ABI-Prism 7300 Sequence Detector (Applied Biosystems).
18S RNA amplification control was used for cycle normalization.
Data were analyzed using the 7500 SDS Software (Applied
Biosystems). All PCR reactions were set up in triplicate.
Fluorescence-activated cell sorting
Flow Cytometry was by fluorescence-activated cell sorting
(FACS). CD63 expression was detected by direct staining with
fluorescein isothiocyanate anti-CD63 (Beckton Dickinson, Frank-
lin Lakes, NJ) for 30 min at 4uC. Cells were then analyzed using a
FACSCalibur flow cytometer (FACScan; BD Biosciences, Moun-
tain View, CA).
Statistical data analysis
All results are expressed as mean 6 standard deviation (SD).
After confirming the normality of the sample distribution and
performing variance analysis, we used the Student t test to
determine significant differences (p value) between two experi-
mental groups.
Results
Mannitol-induced mast cell degranulation is a calcium
dependent process
Mannitol was chosen as a hyperosmolar agent because of its
ability to induce mast cell degranulation. To obtain the optimal
concentration of mannitol for mast cell activation, LAD2 cells
were incubated with a range of concentrations for 30 minutes
(Figure 1A). As shown, all mannitol concentrations caused
degranulation; therefore, the intermediate concentration (10%)
was chosen for further experiments. After mannitol treatment, the
expressions of both b-hexosaminidase release and CD63 were
measured by colorimetric assay and FACS, respectively, as
markers of degranulation. FACS staining allowed us to distinguish
degranulated cells and to discard dead cells with mannitol-induced
toxic effects. Mannitol treated cells induced CD63 expression on
the mast cell surface membrane (Figure 1B).
Next, we extended the study to CD34+ derived HuMC and
HLMC and obtained similar results (Figure 1C). It has been
described that degranulation induced by aggregation of high-
affinity Immunoglobulin E receptor (FceRI) is dependent on the
influx of extracellular calcium across the cell membrane. In
Figure 2. Calcium mobilization, cytokine production and PGE2 secretion are induced by mannitol in LAD2 cells. Determination of
calcium flux following mannitol stimulation (10%) was performed in LAD2 cells loaded with Fluo-4 dye, either with calcium containing media (A) or
without extracellular calcium (B), as described in material and methods section. After defining basal conditions the stimuli was added (time 0) and
measured 10 minutes. Real time polymerase chain reaction was performed in LAD2 cells that were either unstimulated or stimulated with 10%
mannitol, using interleukin-8 and tumor necrosis factor alfa as probes. PMA+ Ionomycin (Sigma) were used as positive control stimuli (C). PGE2 release
was measured at different times as indicated in the figure using an ELISA assay. Results are expressed in pg per 16106 cells (D). Results are triplicates
expressed as mean 6 standard deviation, and are representative of three independent experiments. Statistical significance (* p#0.05, **p#0.01) is
relative to unstimulated control cells. RFU: relative fluorescence units.
doi:10.1371/journal.pone.0110870.g002
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contrast, non-immunological secretagogues can induce degranu-
lation independently of extracellular calcium [37]. Using fluori-
metric analysis, our data show that mannitol was able to release
calcium from both the extracellular (Figure 2A) and the intracel-
lular compartments (Figure 2B). We next analyzed late mast cell
responses by studying TNF and IL-8 production by RT-PCR after
mannitol stimulation compared to PMA and ionomycin stimula-
tion for 6 hours. We demonstrated that mannitol could trigger IL-
8 and TNF production (Figure 2C). Interestingly, mannitol was
able to induce PGE2 secretion as short as 30 minutes as we show
in figure 2D. Collectively, the findings demonstrate that mannitol
induced early and late events in mast cell activation.
PGE2 down regulates mannitol-induced-degranulation in
mast cells
Next, we studied the modulating effects of PGE2 on mannitol-
induced degranulation in human mast cells. First, we performed
quantitative PCR to determine the pattern of expression of EP
receptors by LAD2 cells, and then assayed the LAD2 cell lysates
by western blot using specific antibodies against the EP receptors.
Our data indicate that LAD2 cells express EP2, EP3, and EP4
receptors, but not EP1 receptors (Figure 3A–B). Once the EP
receptor pattern was established, we evaluated the effects of PGE2.
EP receptor stimulation by PGE2 has been reported to enhance
FceRI-mediated mast cell degranulation via EP3 in micromolar
ranges [38], although the positive effect of PGE2 seems to vary
depending on the mast cell type [39]. Since we used an osmotic
stimulus rather than an immunologic stimulus, both the mecha-
nism and intensity may have differed. Therefore, we pre-incubated
LAD2 cells with increasing doses of PGE2 (0.1, 1, and 10 mM) for
10 minutes each, before activating them with 10% mannitol for
30 minutes. A b-hexosaminidase assay was conducted showing
that PGE2 significantly decreased mannitol-induced degranulation
at lower doses (Figure 3C).
PGE2 exerts a protective effect through EP2 and EP4
receptors after mannitol activation
To identify the EP receptors involved in the protective effect,
antagonists of prostanoid receptors were assayed. Our results
reveal that b-hexosaminidase release was only slightly decreased
when low doses of PGE2 were used, but not at the highest
concentration in EP2 and EP4 receptor antagonists pretreated cells
(Figure 4A). Thus, it is unlikely that the EP3 receptor is responsible
for the PGE2-induced reduction of mannitol-induced degranula-
tion. Conversely, when the EP2 (Figure 4B) and EP4 (Figure 4C)
receptors were free, and the EP3 receptors were antagonized,
mediator release was significantly decreased regardless of concen-
tration. In parallel, the EP2 and EP4 receptors mediated increases
in cAMP through activation of adenylyl cyclase, while EP3
receptor has been shown to both inhibit and activate adenylyl
cyclase as well as to drive calcium mobilization [21]. Consistent
with these data, mannitol-induced calcium release was impaired
when EP3 receptors were antagonized (Figure 4D). The data
support a role for EP3 receptors in calcium influx triggered by
PGE2 in mast cells.
We extended these studies by examining the role of PGE2 after
mannitol treatment in CD34+ derived mast cells and HLMC. As
shown in Figure 5, HuMC and LAD2 cell lines responded
similarly, suggesting significant protection when PGE2 acted via
the EP2 and EP4 receptors in CD34+ derived-mast cells
Figure 3. EP2, EP3, and EP4 are expressed on human mast cells. At low doses prostaglandin E2 inhibits mannitol mast cell
degranulation. Real time PCR was performed in LAD2 cells using EP receptor probes as indicated in Table 1 (A). The EP receptors expression levels
were normalized with the b-actin expression level, EP1 expression was undetectable. Western blot analysis was carried out with specific antibodies
against EP1, EP2, EP3, and EP4 in whole cell lysates from CD34
+ derived mast cells and LAD2 cells; blot against b-actin was performed as a loading
control (B). PGE2 titration was carried out before 10% mannitol stimulation in LAD2 cells (C). The experiments are representative of 3 independent
assays. Statistical significance (*p#0.05) is relative to mannitol-stimulated cells.
doi:10.1371/journal.pone.0110870.g003
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(Figure 5A), and that the EP2 receptor appears responsible for
PGE2-driven protection in HLMC (Figure 5B).
PGE2 interferes with Phosphatidyl Inositide 3-Kinase and
Mitogen-Activated Protein Kinase Signaling after
Mannitol Stimulation
We assessed the effects of PGE2 in the phosphorylation of
proteins after mast cell activation by osmotic changes. To do so,
we examined the phosphatidyl inositide 3-kinase (PI3K) and
mitogen-activated protein kinase (MAPK) pathways by western
blot analysis in LAD2 (Figure 6A) and HMC-1 cells (Figure 6B).
The phosphorylation status of AKT (Protein Kinase B) was
assayed as a surrogate marker for PI3K activation. AKT
phosphorylation was decreased under conditions where the EP3
receptor was blocked in mannitol treated cells, indicating a
decrease in PI3K activation/OK (Figure 6A). AKT was constitu-
tively increased in HMC-1 cell lines in which the KIT receptor
was mutated and delivered signals independently of ligand
engagement (data not shown). PGE2 prevented mannitol-induced
phosphorylation of ERK1/2, p38, and JNK in LAD2 and HMC-1
cell lines when the EP3 receptor was blocked (Figure 6A, B).
Together, these results indicate that PGE2 exhibits inhibitory
effects on mannitol-induced osmotic activation by binding to EP2
or EP4 receptors in human mast cells.
Discussion
This study aimed to evaluate the protective effect of PGE2 on
mannitol-induced mast cell activation as a model of EIB in
Asthma, where mannitol was used as a hyperosmolar stimulus.
The use of a hypertonic agent stems from the theory that EIB is
caused by increased osmolarity of the surface of the airways
through the release of proinflammatory mediators [8]. Previous
in vitro work on HLMCs showed that hyperosmolar stimulation
induced histamine release, suggesting that hyperosmolar mediated
release was a mechanism by which exercise-induced hyperventi-
lation might induce asthma [40]. Our results show that mannitol
induces mast cell signaling events that are possibly involved in the
inflammatory response observed in asthma.
At early stages, mannitol increased degranulation in a calcium
dependent manner before IL-8 and TNF alfa production
occurred. Mannitol triggered the activation of PI3K and MAPK
cascades, which enhanced ERK1/2, p38 and JNK phosphoryla-
tion. The MAPK pathway activates transcription factors such as
AP-1 that in turn regulate cytokine and metalloprotease produc-
tion [41]. Additionally ERK1/2 phosphorylates cytoplasmic
phospholipase A2, which is involved in the production of the
eicosanoid precursor arachidonic acid [42,43]. Interestingly,
previous studies reported ERK phosphorylation in airway smooth
muscle cells that cause increased production of both IL-1b and
granulocyte-macrophage colony-stimulating factor, which are
Figure 4. Mannitol-induced b-hexosaminidase release and calcium mobilization were altered in the presence of prostaglandin E2
and prostanoid receptor antagonists in LAD2 cells. b-Hexosaminidase release was conducted in mannitol-stimulated LAD2 cells pre-treated
with antagonist to PGE2 receptors for 10 minutes and PGE2 at various doses (0, 1, 1, 10 mM). EP2 and EP4 receptor antagonists (AH6809, AH23848 at
10 mM), (A); EP3 and EP4 receptor antagonists (L826266 30 mM and AH23848 at 10 mM) (B); and, EP2 and EP3 receptor antagonists (AH6809 at 10 mM
and L826266 at 30 mM) (C). Results are in triplicate and are the mean of three independent experiments expressed as mean 6 standard deviation.
Calcium mobilization was performed in cells that were left untreated or treated with 10% mannitol, 10% mannitol plus prostaglandin E2 (1 mM), or
pretreated with an EP3 antagonist (L826266 at 30 mM) for 10 minutes and then stimulated with 10% mannitol and prostaglandin E (1 mM),2 (D). After
defining basal conditions the stimuli was added (time 0) and measured 10 minutes. Statistical significance (*p#0.05, **p#0.01, ***p#0.001) is relative
to mannitol-stimulated cells.
doi:10.1371/journal.pone.0110870.g004
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involved in the contractile response and remodeling of the airways
in asthma [43]. The role of JNK in asthma is related to
extracellular matrix deposition, with its activation causing the
release of growth factors such as transforming growth factor beta,
which may explain the phenotype transition from fibroblasts to
myofibroblasts in the lung [44]. Moreover, p38 regulates the
antigen-triggered migration of mast cells and mediates the
production of IL-8.
PGE2 is a highly pluripotent prostanoid displaying a wide range
of effects, including smooth muscle relaxation and contraction,
and both pro-inflammatory and anti-inflammatory properties
[21]. These opposing effects are possible due to the presence of at
least four subclasses of EP receptors (EP1–4) [45]. It has been
reported that CD34+ derived mast cells express the PGE2
receptors EP2, EP3, and EP4 [38]. Our data shows that the
LAD2 cell line has a similar PGE2 receptor pattern.
The aim of the study was to evaluate how PGE2 modulates the
response to mannitol through prostanoid receptors as a model of
exercise-induced asthma in human mast cells. For that reason we
used antagonist of the receptor instead of direct agonist of them. It
has to be noted that AH6809, antagonist for EP2, is also known to
interact with DP1, and AH23848, a EP4 antagonist, can interact
also with the TP receptors. DP1 has been suggested to be
expressed on murine mast cells having a role on murine mast cell
maturation and differentiation [46]. In our experiments, we are
dealing basically with mature human mast cell systems subject to a
short term incubation with AH6809. No such maturation effect is
expected under our circumstances/conditions. Regarding
AH23848, there is very little information on the presence of TP
receptors on the human mast cells surface. In fact, it has been
reported that the TP agonits U-46619 has no effect on human
mast cells [47].
We found that when PGE2 triggers the EP3 receptor, it exerts a
limited protective effect on mannitol-induced mast cell degranu-
lation. In contrast, when PGE2 acts through EP2 and EP4
receptors, mannitol-induced mast cell degranulation and calcium
influx are significantly nullified. Our data agree with other studies
in which PGE2 has been shown to work through EP2 receptors to
stabilize lung mast cells after IgE dependent activation [21,47] and
with studies reporting that the EP2 agonist butaprost exerts a
protective effect in allergen-sensitized mice [27]. Additionally, a
recent study using human bronchial smooth muscle proposes that
PGE2-induced relaxation is mediated via the EP4 receptor [48],
which contrasts with reported role of the EP3 receptor in the
induction of PGE2 airway irritability and cough [49].
Gas, the EP2 and EP4 receptor stimulation protein, results in
adenylate cyclase activation and intracellular cAMP production.
Conversely, EP3 receptor signaling is predominantly coupled to
protein Gai and produces reduced cAMP levels [50]. The
accumulation of cAMP promoted by EP2 and EP4 receptors is
associated with inhibition of cell function, whereas intracellular
calcium increases induced by the EP3 receptor are linked to
cellular activation [51]. The evidence from this study, along with
other reports, supports the notion that PGE2 stabilizes mast cells
through the EP2 and/or EP4 receptors, thereby providing control
of the deleterious effects of mast cell degranulation in the airways.
The presence of various EP3 isoforms could explain the differential
release of mediators in degranulation assays at different PGE2
concentrations. It has been reported that, by interacting with the
EP3 receptor, higher doses of PGE2 increase mediator release
through IgE dependent mechanisms [52]. In addition, the
presence of several EP3 isoforms might explain the protective
effects of EP3 in suppressing allergic inflammation in mice [53].
Additionaly, it should be noted that the EP receptors expression
pattern has been reported to be different in murine mast cells. EP1,
EP3, and EP4 transcripts have been found in IL-3-dependent
murine mast cell line, MC/9 [54] and murine bone marrow
derived mast cells [55]. but not EP2. Our data in LAD2 cells is
supported by the data obtained in CD34+ derived cells and
HLMCs where the decrease in mannitol-induced degranulation
was significant when the EP2 and EP4 receptors were free to
interact with PGE2.
The mannitol stimulus caused increased activation in both
MAPK and PI3K signaling pathways in mast cells. PGE2
modulated the mannitol phosphorylation profile of these pathways
differently according to the receptor that was triggered. Thus,
when the EP3 receptor was involved, ERK1/2, p38, and JNK
phosphorylation remained active, while their phosphorylation
decreased with EP2 or EP4 receptor engagement. Our results
suggest that PGE2 is not only able to modulate early mast cell
events through degranulation, but that it can regulate downstream
Figure 5. Prostaglandin E2 impairs mannitol-induced degran-
ulation in human mast cells through the prostanoid receptors
EP2 and/or EP4. Human CD34
+ derived-mast cell (A) and human lung
mast cell (B) degranulation was induced by 10% mannitol and
prostaglandin E2 at 1 mM in the presence or absence of prostanoid
receptor antagonists as indicated in the figure at doses indicated in
material and methods section. Results are in triplicate and are the mean
of three independent experiments expressed as mean 6 SD. Statistical
significance (*p#0.05) is relative to mannitol-stimulated cells.
doi:10.1371/journal.pone.0110870.g005
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events that may perpetuate airway inflammation in diseases such
as asthma.
Experimental treatment with PGE2 prevents exercise–induced
airway obstruction [13]. The preventive effects of exogenous
effects of PGE2 on EIB might suggest that an insufficient
biosynthesis of endogenous PGE2 during exercise in asthma
patients can contribute to exercise-induced bronchoconstriction.
Interestingly, exercise increases PGE2 release in the airways of
healthy subjects [56], but this increase is not detected in asthma
patients [57].
In conclusion, we have provided functional in vitro evidence
that EP2/EP4 are potential therapeutical targets having a role in
the regulation of MC degranulation that may prevent EIB in
asthma by nullifying the hyperosmolar-induced degranulation of
airway mast cells.
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